PREMARIN (conjugated estrogens) by Pfizer is estrogen receptor agonists [moa]. First approved in 1956.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
PREMARIN is a conjugated estrogen injectable approved in 1956 that works as an estrogen receptor agonist. It is used for hormone replacement therapy and other estrogen-deficiency conditions in women. The drug is administered via injection and represents a foundational estrogen therapy in the market.
As PREMARIN approaches loss of exclusivity with moderate competitive pressure, commercial teams should anticipate resource reallocation and increased focus on market defense strategies.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
Premarin Versus Toviaz for Treatment of Overactive Bladder
A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.
Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene
Worked on PREMARIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on PREMARIN offers experience managing a legacy franchise with strong brand equity and a mature patient base. However, the approaching loss of exclusivity and limited pipeline activity suggest this is better suited for professionals focused on market defense and lifecycle optimization rather than launch or growth acceleration.